Lilly plans to spend nearly $4 billion to acquire three vaccine R&D companies
Eli Lilly is reportedly planning to acquire three vaccine development companies in a deal potentially worth nearly $4 billion. The acquisitions include Limmatech for up to $780 million, Vaccine Co for up to $1.55 billion, and Curevo for up to $1.5 billion, all to be paid in cash. This cluster also mentions Honeywell's quantum computing subsidiary Quantinuum filing for an IPO to raise up to $1.05 billion, and the execution of Xu Yao, former CEO of Trisolaris, for a poisoning case. AI
IMPACT This cluster is primarily about pharmaceutical and quantum computing industry financial moves, with minimal direct impact on AI operators.